1.09 USD
+0.07 (+6.86%)
Taking everything into account, NBY scores 2 out of 10 in our fundamental rating. NBY was compared to 192 industry peers in the Pharmaceuticals industry. NBY may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NBY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NBY had negative earnings in the past year.
In the past year NBY has reported a negative cash flow from operations.
NBY had negative earnings in each of the past 5 years.
In the past 5 years NBY always reported negative operating cash flow.
1.2 Ratios
NBY's Return On Assets of -251.48% is on the low side compared to the rest of the industry. NBY is outperformed by 92.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -251.48% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NBY (66.26%) is better than 73.96% of its industry peers.
NBY's Gross Margin has declined in the last couple of years.
NBY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.26% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
2. Health
2.1 Basic Checks
NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
NBY has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NBY has more shares outstanding
Compared to 1 year ago, NBY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -54.09, we must say that NBY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -54.09, NBY is not doing good in the industry: 93.23% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -54.09 |
ROIC/WACCN/A
WACC9.88%
2.3 Liquidity
NBY has a Current Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
NBY has a worse Current ratio (0.68) than 90.63% of its industry peers.
A Quick Ratio of 0.41 indicates that NBY may have some problems paying its short term obligations.
NBY's Quick ratio of 0.41 is on the low side compared to the rest of the industry. NBY is outperformed by 92.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 84.82% over the past year.
The Revenue for NBY has decreased by -33.58% in the past year. This is quite bad
NBY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.19% yearly.
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
3.2 Future
Based on estimates for the next years, NBY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.55% on average per year.
The Revenue is expected to grow by 21.46% on average over the next years. This is a very strong growth
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NBY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NBY's earnings are expected to grow with 31.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NBY has a Yearly Dividend Yield of 73.39%, which is a nice return.
The stock price of NBY dropped by -38.76% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
NBY's Dividend Yield is rather good when compared to the industry average which is at 6.85. NBY pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.34, NBY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 73.39% |
5.2 History
NBY does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y31.55%
EPS Next 3YN/A
NYSEARCA:NBY (11/28/2025, 7:50:24 PM)
1.09
+0.07 (+6.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners21.28%
Inst Owner Change3.72%
Ins Owners0.02%
Ins Owner Change0%
Market Cap137.35M
Revenue(TTM)9.78M
Net Income(TTM)-8.61M
Analysts80
Price Target0.87 (-20.18%)
Short Float %2.43%
Short Ratio0.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 73.39% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.67%
Min Revenue beat(2)-27.48%
Max Revenue beat(2)-7.85%
Revenue beat(4)0
Avg Revenue beat(4)-20.15%
Min Revenue beat(4)-27.48%
Max Revenue beat(4)-7.85%
Revenue beat(8)2
Avg Revenue beat(8)-7.51%
Revenue beat(12)4
Avg Revenue beat(12)-7.15%
Revenue beat(16)5
Avg Revenue beat(16)-5.76%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.41
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.08
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -251.48% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.26% | ||
| FCFM | N/A |
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score4
Asset Turnover2.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15% | ||
| Cap/Sales | 0.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.68 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -54.09 |
F-Score4
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3YN/A
OCF growth 5YN/A
NOVABAY PHARMACEUTICALS INC / NBY FAQ
Can you provide the ChartMill fundamental rating for NOVABAY PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 2 / 10 to NBY.
What is the valuation status for NBY stock?
ChartMill assigns a valuation rating of 1 / 10 to NOVABAY PHARMACEUTICALS INC (NBY). This can be considered as Overvalued.
What is the profitability of NBY stock?
NOVABAY PHARMACEUTICALS INC (NBY) has a profitability rating of 1 / 10.
How financially healthy is NOVABAY PHARMACEUTICALS INC?
The financial health rating of NOVABAY PHARMACEUTICALS INC (NBY) is 0 / 10.
What is the expected EPS growth for NOVABAY PHARMACEUTICALS INC (NBY) stock?
The Earnings per Share (EPS) of NOVABAY PHARMACEUTICALS INC (NBY) is expected to grow by 39.01% in the next year.